Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives
Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In...
Ausführliche Beschreibung
Autor*in: |
López-Gómez, Miriam [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2016transfer abstract |
---|
Schlagwörter: |
---|
Umfang: |
18 |
---|
Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:107 ; year:2016 ; pages:54-71 ; extent:18 |
Links: |
---|
DOI / URN: |
10.1016/j.critrevonc.2016.08.006 |
---|
Katalog-ID: |
ELV040154769 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV040154769 | ||
003 | DE-627 | ||
005 | 20230625231031.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.critrevonc.2016.08.006 |2 doi | |
028 | 5 | 2 | |a GBVA2016018000014.pica |
035 | |a (DE-627)ELV040154769 | ||
035 | |a (ELSEVIER)S1040-8428(16)30183-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.52 |2 bkl | ||
100 | 1 | |a López-Gómez, Miriam |e verfasserin |4 aut | |
245 | 1 | 0 | |a Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
264 | 1 | |c 2016transfer abstract | |
300 | |a 18 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. | ||
520 | |a Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. | ||
650 | 7 | |a Molecular markers |2 Elsevier | |
650 | 7 | |a Gastrointestinal tumors |2 Elsevier | |
650 | 7 | |a Cancer stem cells |2 Elsevier | |
650 | 7 | |a Drug resistance |2 Elsevier | |
700 | 1 | |a Casado, Enrique |4 oth | |
700 | 1 | |a Muñoz, Marta |4 oth | |
700 | 1 | |a Alcalá, Sonia |4 oth | |
700 | 1 | |a Moreno-Rubio, Juan |4 oth | |
700 | 1 | |a D’Errico, Gabriele |4 oth | |
700 | 1 | |a Jiménez-Gordo, Ana María |4 oth | |
700 | 1 | |a Salinas, Silvia |4 oth | |
700 | 1 | |a Sainz, Bruno |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
773 | 1 | 8 | |g volume:107 |g year:2016 |g pages:54-71 |g extent:18 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2016.08.006 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2016 | ||
912 | |a GBV_ILN_2048 | ||
936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
951 | |a AR | ||
952 | |d 107 |j 2016 |h 54-71 |g 18 | ||
953 | |2 045F |a 610 |
author_variant |
m l g mlg |
---|---|
matchkey_str |
lpezgmezmiriamcasadoenriquemuozmartaalca:2016----:urneiecfracrtmeligsritsiatmradu |
hierarchy_sort_str |
2016transfer abstract |
bklnumber |
44.52 |
publishDate |
2016 |
allfields |
10.1016/j.critrevonc.2016.08.006 doi GBVA2016018000014.pica (DE-627)ELV040154769 (ELSEVIER)S1040-8428(16)30183-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl López-Gómez, Miriam verfasserin aut Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives 2016transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Elsevier Casado, Enrique oth Muñoz, Marta oth Alcalá, Sonia oth Moreno-Rubio, Juan oth D’Errico, Gabriele oth Jiménez-Gordo, Ana María oth Salinas, Silvia oth Sainz, Bruno oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:107 year:2016 pages:54-71 extent:18 https://doi.org/10.1016/j.critrevonc.2016.08.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 107 2016 54-71 18 045F 610 |
spelling |
10.1016/j.critrevonc.2016.08.006 doi GBVA2016018000014.pica (DE-627)ELV040154769 (ELSEVIER)S1040-8428(16)30183-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl López-Gómez, Miriam verfasserin aut Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives 2016transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Elsevier Casado, Enrique oth Muñoz, Marta oth Alcalá, Sonia oth Moreno-Rubio, Juan oth D’Errico, Gabriele oth Jiménez-Gordo, Ana María oth Salinas, Silvia oth Sainz, Bruno oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:107 year:2016 pages:54-71 extent:18 https://doi.org/10.1016/j.critrevonc.2016.08.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 107 2016 54-71 18 045F 610 |
allfields_unstemmed |
10.1016/j.critrevonc.2016.08.006 doi GBVA2016018000014.pica (DE-627)ELV040154769 (ELSEVIER)S1040-8428(16)30183-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl López-Gómez, Miriam verfasserin aut Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives 2016transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Elsevier Casado, Enrique oth Muñoz, Marta oth Alcalá, Sonia oth Moreno-Rubio, Juan oth D’Errico, Gabriele oth Jiménez-Gordo, Ana María oth Salinas, Silvia oth Sainz, Bruno oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:107 year:2016 pages:54-71 extent:18 https://doi.org/10.1016/j.critrevonc.2016.08.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 107 2016 54-71 18 045F 610 |
allfieldsGer |
10.1016/j.critrevonc.2016.08.006 doi GBVA2016018000014.pica (DE-627)ELV040154769 (ELSEVIER)S1040-8428(16)30183-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl López-Gómez, Miriam verfasserin aut Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives 2016transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Elsevier Casado, Enrique oth Muñoz, Marta oth Alcalá, Sonia oth Moreno-Rubio, Juan oth D’Errico, Gabriele oth Jiménez-Gordo, Ana María oth Salinas, Silvia oth Sainz, Bruno oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:107 year:2016 pages:54-71 extent:18 https://doi.org/10.1016/j.critrevonc.2016.08.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 107 2016 54-71 18 045F 610 |
allfieldsSound |
10.1016/j.critrevonc.2016.08.006 doi GBVA2016018000014.pica (DE-627)ELV040154769 (ELSEVIER)S1040-8428(16)30183-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl López-Gómez, Miriam verfasserin aut Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives 2016transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Elsevier Casado, Enrique oth Muñoz, Marta oth Alcalá, Sonia oth Moreno-Rubio, Juan oth D’Errico, Gabriele oth Jiménez-Gordo, Ana María oth Salinas, Silvia oth Sainz, Bruno oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:107 year:2016 pages:54-71 extent:18 https://doi.org/10.1016/j.critrevonc.2016.08.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 107 2016 54-71 18 045F 610 |
language |
English |
source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:107 year:2016 pages:54-71 extent:18 |
sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:107 year:2016 pages:54-71 extent:18 |
format_phy_str_mv |
Article |
bklname |
Therapie |
institution |
findex.gbv.de |
topic_facet |
Molecular markers Gastrointestinal tumors Cancer stem cells Drug resistance |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
miR-214 in stroma cells and tumor progression |
authorswithroles_txt_mv |
López-Gómez, Miriam @@aut@@ Casado, Enrique @@oth@@ Muñoz, Marta @@oth@@ Alcalá, Sonia @@oth@@ Moreno-Rubio, Juan @@oth@@ D’Errico, Gabriele @@oth@@ Jiménez-Gordo, Ana María @@oth@@ Salinas, Silvia @@oth@@ Sainz, Bruno @@oth@@ |
publishDateDaySort_date |
2016-01-01T00:00:00Z |
hierarchy_top_id |
ELV019637179 |
dewey-sort |
3610 |
id |
ELV040154769 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040154769</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231031.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2016.08.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040154769</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(16)30183-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">López-Gómez, Miriam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular markers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gastrointestinal tumors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug resistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casado, Enrique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muñoz, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alcalá, Sonia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moreno-Rubio, Juan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D’Errico, Gabriele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiménez-Gordo, Ana María</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salinas, Silvia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sainz, Bruno</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:107</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:54-71</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2016.08.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">107</subfield><subfield code="j">2016</subfield><subfield code="h">54-71</subfield><subfield code="g">18</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
López-Gómez, Miriam |
spellingShingle |
López-Gómez, Miriam ddc 610 bkl 44.52 Elsevier Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
authorStr |
López-Gómez, Miriam |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 610 VZ 44.52 bkl Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance Elsevier |
topic |
ddc 610 bkl 44.52 Elsevier Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance |
topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance |
topic_browse |
ddc 610 bkl 44.52 Elsevier Molecular markers Elsevier Gastrointestinal tumors Elsevier Cancer stem cells Elsevier Drug resistance |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
e c ec m m mm s a sa j m r jmr g d gd a m j g amj amjg s s ss b s bs |
hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
hierarchy_parent_id |
ELV019637179 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV019637179 |
title |
Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
ctrlnum |
(DE-627)ELV040154769 (ELSEVIER)S1040-8428(16)30183-4 |
title_full |
Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
author_sort |
López-Gómez, Miriam |
journal |
miR-214 in stroma cells and tumor progression |
journalStr |
miR-214 in stroma cells and tumor progression |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2016 |
contenttype_str_mv |
zzz |
container_start_page |
54 |
author_browse |
López-Gómez, Miriam |
container_volume |
107 |
physical |
18 |
class |
610 610 DE-600 610 VZ 44.52 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
López-Gómez, Miriam |
doi_str_mv |
10.1016/j.critrevonc.2016.08.006 |
dewey-full |
610 |
title_sort |
current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
title_auth |
Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
abstract |
Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. |
abstractGer |
Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. |
abstract_unstemmed |
Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
title_short |
Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives |
url |
https://doi.org/10.1016/j.critrevonc.2016.08.006 |
remote_bool |
true |
author2 |
Casado, Enrique Muñoz, Marta Alcalá, Sonia Moreno-Rubio, Juan D’Errico, Gabriele Jiménez-Gordo, Ana María Salinas, Silvia Sainz, Bruno |
author2Str |
Casado, Enrique Muñoz, Marta Alcalá, Sonia Moreno-Rubio, Juan D’Errico, Gabriele Jiménez-Gordo, Ana María Salinas, Silvia Sainz, Bruno |
ppnlink |
ELV019637179 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth |
doi_str |
10.1016/j.critrevonc.2016.08.006 |
up_date |
2024-07-06T16:47:34.804Z |
_version_ |
1803848992481607680 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040154769</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231031.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2016.08.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040154769</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(16)30183-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">López-Gómez, Miriam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer stem cells (CSCs) are a very heterogeneous subpopulation of “stem-like” cancer cells that have been identified in many cancers, including leukemias and solid tumors. It is believed that CSCs drive tumor growth, malignant behavior and are responsible for the initiation of metastatic spread. In addition, CSCs have been implicated in chemotherapy and radiotherapy resistance. Current evidence supports the theory that CSCs share at least two main features of normal stem cells: self-renewal and differentiation, properties that contribute to tumor survival even in the presence of aggressive chemotherapy; however, the mechanism(s) governing the unique biology of CSCs remain unclear. In the field of gastrointestinal cancer, where we face very low survival rates across different tumor types, unraveling the role of CSCs in gastrointestinal tumors should improve our knowledge of cancer biology and chemoresistance, ultimately benefiting patient survival. Towards this end, much effort is being invested in the characterization of CSCs as a means of overcoming drug resistance and controlling metastatic spread. In this review we will cover the concept of CSCs, the current evidence for CSCs in gastrointestinal tumors and future research directions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular markers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gastrointestinal tumors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug resistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casado, Enrique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muñoz, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alcalá, Sonia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moreno-Rubio, Juan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D’Errico, Gabriele</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiménez-Gordo, Ana María</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salinas, Silvia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sainz, Bruno</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:107</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:54-71</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2016.08.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">107</subfield><subfield code="j">2016</subfield><subfield code="h">54-71</subfield><subfield code="g">18</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.400529 |